WHOCC
Postal address:
WHO Collaborating Centre for Drug Statistics Methodology
Norwegian Institute of Public Health
Postboks 222 Skøyen
0213 Oslo
Norway

Visiting/delivery address:
Sandakerveien 24C
Bygg C
0473 Oslo
Norway

Tel:  +47 21 07 81 60
E-mail:
 
Copyright/Disclaimer

DDDs

List of temporary DDDs decided at the latest meetings of the WHO International Working Group for Drug Statistics Methodology. Comments or objections to the ATC codes should be forwarded to the WHO Collaborating Centre for Drug Statistics Methodology within the deadline. If no objections are received, the new DDDs will be considered final and included in the ATC/DDD Index. The year of implementation in the ATC/DDD Index is given in the list.

ATC codeATC level name (INN/generic name)DDDUnit Adm.routeDeadline for objection to temporary DDDs Implementation in ATC/DDD index if no objection is received
A10BJ06semaglutide10.5mgO01.02.20212022
A16AB15velmanase alfa10mgP01.02.20212022
B03XA06luspatercept3.33mgP01.02.20212022
C08EX02perhexiline0.2gO01.02.20212022
J01MA15gemifloxacin0.2gP01.02.20212022
J05AB16remdesivir0.1gP01.02.20212022
J05AH01zanamivir1.2gP01.02.20212022
L01EA01imatinib0.4gO01.02.20212022
L01EA02dasatinib0.1gO01.02.20212022
L01EA03nilotinib0.6gO01.02.20212022
L01EA04bosutinib0.4gO01.02.20212022
L01EA05ponatinib45mgO01.02.20212022
L01EB01gefitinib0.25gO01.02.20212022
L01EB02erlotinib0.15gO01.02.20212022
L01EB03afatinib40mgO01.02.20212022
L01EB04osimertinib80mgO01.02.20212022
L01EB07dacomitinib45mgO01.02.20212022
L01EC01vemurafenib1.92gO01.02.20212022
L01EC02dabrafenib0.3gO01.02.20212022
L01EC03encorafenib0.45gO01.02.20212022
L01ED01crizotinib 0.5gO01.02.20212022
L01ED02ceritinib0.45gO01.02.20212022
L01ED03alectinib1.2gO01.02.20212022
L01ED04brigatinib0.18gO01.02.20212022
L01ED05lorlatinib0.1gO01.02.20212022
L01EE01trametinib2mgO01.02.20212022
L01EE02cobimetinib45mgO01.02.20212022
L01EE03binimetinib90mgO01.02.20212022
L01EF01palbociclib94mgO01.02.20212022
L01EF02ribociclib0.45gO01.02.20212022
L01EF03abemaciclib0.3gO01.02.20212022
L01EG01temsirolimus3.57mgP01.02.20212022
L01EG02everolimus10mgO01.02.20212022
L01EH01lapatinib1.25gO01.02.20212022
L01EH02neratinib0.24gO01.02.20212022
L01EH03tucatinib0.6gO01.02.20212022
L01EJ01ruxolitinib30mgO01.02.20212022
L01EJ02fedratinib0.4gO01.02.20212022
L01EK01axitinib10mgO01.02.20212022
L01EK03tivozanib1mgO01.02.20212022
L01EL01ibrutinib0.42gO01.02.20212022
L01EL02acalabrutinib0.2gO01.02.20212022
L01EL03zanubrutinib0.32gO01.02.20212022
L01EM01idelalisib0.3gO01.02.20212022
L01EM02copanlisib6.43mgO01.02.20212022
L01EM03alpelisib0.3gO01.02.20212022
L01EM04duvelisib50mgO01.02.20212022
L01EX01sunitinib33mgO01.02.20212022
L01EX02sorafenib0.8gO01.02.20212022
L01EX03pazopanib0.8gO01.02.20212022
L01EX04vandetanib0.3gO01.02.20212022
L01EX05regorafenib0.12gO01.02.20212022
L01EX07cabozantinib60mgO01.02.20212022
L01EX08lenvatinib18mgO01.02.20212022
L01EX09nintedanib0.38gO01.02.20212022
L01EX10midostaurin0.1gO01.02.20212022
L01EX12larotrectinib0.2gO01.02.20212022
L01EX13gilteritinib0.12gO01.02.20212022
L01EX14entrectinib0.6gO01.02.20212022
L01EX15pexidartinib0.8gO01.02.20212022
L01EX16erdafitinib9mgO01.02.20212022
L01EX17capmatinib0.8gO01.02.20212022
L01EX18avapritinib0.3gO01.02.20212022
L01EX19ripretinib0.15gO01.02.20212022
L01EX20pemigatinib9mgO01.02.20212022
L01EX22selpercatinib0.32gO01.02.20212022
L01EX23pralsetinib0.4g O01.02.20212022
L02BB06darolutamide1.2gO01.02.20212022
L04AA38ozanimod0.92mgO01.02.20212022
N02BG11mirogabalin25mgO01.02.20212022
N03AX24cannabidiol0.7gO01.02.20212022
N05AL05amisulpride7.5mgP01.02.20212022
N06AX27esketamine8mgN01.02.20212022
V03AG05sodium phosphate8gO01.02.20212022

Last updated: 2020-11-27